Hiromichi Fujino

Profile Information

Affiliation: professor, Graduate School of Pharmaceutical Sciences, Tokushima University

J-GLOBAL ID: 201901006097823867
researchmap Member ID: B000378991

Research Interests

Research Areas

Life sciences / Pharmacology /

Papers

CA9 and PRELID2; hypoxia-responsive potential therapeutic targets for pancreatic ductal adenocarcinoma as per bioinformatics analyses.

Masaki Imanishi, Takahisa Inoue, Keijo Fukushima, Ryosuke Yamashita, Ryo Nakayama, Masataka Nojima, Kosuke Kondo, Yoshiki Gomi, Honoka Tsunematsu, Kohei Goto …

Journal of pharmacological sciences, 153(4) 232-242, Dec, 2023
Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease

Yuya Horinouchi, Yuka Murashima, Yuto Yamada, Shun Yoshioka, Keijo Fukushima, Takumi Kure, Naofumi Sasaki, Masaki Imanishi, Hiromichi Fujino, Koichiro Tsuchiya …

Life Sciences, 321 121590-121590, May, 2023
Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the United States Food and Drug Administration Adverse Event Reporting System.

Takahiro Niimura, Yoshito Zamami, Koji Miyata, Takahisa Mikami, Mizuho Asada, Keijo Fukushima, Masaki Yoshino, Satoru Mitsuboshi, Naoto Okada, Hirofumi Hamano …

Journal of clinical pharmacology, 63(4) 473-479, Dec 1, 2022
PARP14 regulates EP4 receptor expression in human colon cancer HCA-7 cells.

Masato Mashimo, Asuka Shimizu, Aimi Mori, Ayaka Hamaguchi, Keijo Fukushima, Naofumi Seira, Takeshi Fujii, Hiromichi Fujino

Biochemical and biophysical research communications, 623 133-139, Oct 1, 2022
Phosphatidylcholine-Plasmalogen-Oleic Acid Has Protective Effects against Arachidonic Acid-Induced Cytotoxicity.

Natsuki Yamagiwa, Haruka Kobayashi, Haruka Okabayashi, Miki Yasuda, Keijo Fukushima, Jun Kawamura, Satoshi Kotoura, Hiromichi Fujino

Biological & pharmaceutical bulletin, 45(5) 643-648, May 1, 2022
Down-regulation of the expression of cyclooxygenase-2 and prostaglandin E2 by interleukin-4 is mediated via a reduction in the expression of prostanoid EP4 receptors in HCA-7 human colon cancer cells.

Kana Kitagawa, Ayaka Hamaguchi, Keijo Fukushima, Yuki Nakano, John W Regan, Masato Mashimo, Hiromichi Fujino

European journal of pharmacology, 920 174863-174863, Apr 5, 2022
The Gαs-protein-mediated pathway may be steadily stimulated by prostanoid EP2 receptors, but not by EP4 receptors.

Keijo Fukushima, Kanaho Senoo, Naoki Kurata, John W Regan, Hiromichi Fujino

FEBS open bio, 12(4) 775-783, Apr, 2022
Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data.

Yoshito Zamami, Takahiro Niimura, Takehiro Kawashiri, Mitsuhiro Goda, Yutaro Naito, Keijo Fukushima, Soichiro Ushio, Fuka Aizawa, Hirofumi Hamano, Naoto Okada …

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 148 112744-112744, Apr, 2022
Foreword.

Hiromichi Fujino

Biological & pharmaceutical bulletin, 45(6) 668-668, 2022
The Biased Activities of Prostanoids and Their Receptors: Review and Beyond.

Hiromichi Fujino

Biological & pharmaceutical bulletin, 45(6) 684-690, 2022
Identification and Characterization of Human Colorectal Cancer Cluster Predominantly Expressing EP3 Prostanoid Receptor Subtype.

Keijo Fukushima, Hiromichi Fujino

Biological & pharmaceutical bulletin, 45(6) 698-702, 2022
Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity.

Hirofumi Hamano, Yasumasa Ikeda, Mitsuhiro Goda, Keijo Fukushima, Seiji Kishi, Masayuki Chuma, Michiko Yamashita, Takahiro Niimura, Kenshi Takechi, Masaki Imanishi …

Kidney international, 99(4) 885-899, Apr, 2021
The differential functional coupling of phosphodiesterase 4 to human DP and EP2 prostanoid receptors stimulated with PGD2 or PGE2.

Iori Okura, Nanae Hasuoka, Kanaho Senoo, Akiko Suganami, Keijo Fukushima, John W Regan, Masato Mashimo, Toshihiko Murayama, Yutaka Tamura, Hiromichi Fujino

Pharmacological reports : PR, 73(3) 946-953, Mar 30, 2021
Development of a mugineic acid family phytosiderophore analog as an iron fertilizer.

Motofumi Suzuki, Atsumi Urabe, Sayaka Sasaki, Ryo Tsugawa, Satoshi Nishio, Haruka Mukaiyama, Yoshiko Murata, Hiroshi Masuda, May Sann Aung, Akane Mera …

Nature communications, 12(1) 1558-1558, Mar 10, 2021
Why PGD2 has different functions from PGE2.

Hiromichi Fujino

BioEssays : news and reviews in molecular, cellular and developmental biology, 43(2) e2000213, Feb, 2021
15-Keto-PGE2 acts as a biased/partial agonist to terminate PGE2-evoked signaling.

Suzu Endo, Akiko Suganami, Keijo Fukushima, Kanaho Senoo, Yumi Araki, John W Regan, Masato Mashimo, Yutaka Tamura, Hiromichi Fujino

The Journal of biological chemistry, 295(38) 13338-13352, Sep 18, 2020
Fibroblast-specific ERK5 deficiency changes tumor vasculature and exacerbates tumor progression in a mouse model.

Masaki Imanishi, Yusuke Yamakawa, Keijo Fukushima, Raiki Ikuto, Akiko Maegawa, Yuki Izawa-Ishizawa, Yuya Horinouchi, Masateru Kondo, Masatoshi Kishuku, Mitsuhiro Goda …

Naunyn-Schmiedeberg's archives of pharmacology, Apr 19, 2020 Peer-reviewed
Identification of pyrogallol from Awa-tea as an anti-allergic compound that suppresses nasal symptoms and IL-9 gene expression.

Tomohiro Nakano, Mitsuhiro Ikeda, Tomoharu Wakugawa, Yoshiki Kashiwada, Osamu Kaminuma, Noriko Kitamura, Masam Yabumoto, Hiromichi Fujino, Yoshiaki Kitamura, Hiroyuki Fukui …

The journal of medical investigation : JMI, 67(3.4) 289-297, 2020
PGE(1) and E-3 show lower efficacies than E-2 to beta- catenin-mediated activity as biased ligands of EP4 prostanoid receptors

Yumi Araki, Akiko Suganami, Suzu Endo, Yuta Masuda, Keijo Fukushima, John W. Regan, Toshihiko Murayama, Yutaka Tamura, Hiromichi Fujino

FEBS LETTERS, 591(22) 3771-3780, Nov, 2017 Peer-reviewed
Anti-cancer Effects of MW-03， a Novel Indole Compound， by Inducing 15-Hydroxyprostaglandin Dehydrogenase and Cellular Growth Inhibition in the LS174T Human Colon Cancer Cell Line.

Seira N, Yanagisawa N, Suganami A, Honda T, Wasai M, Regan JW, Fukushima K, Yamaguchi N, Tamura Y, Arai T …

Biological & pharmaceutical bulletin, 40(10) 1806-1812, Jan, 2017 Peer-reviewed

Misc.

シスプラチン誘発性腎障害を予防する既存薬物の同定と検証

濱野裕章, 池田康将, 合田光寛, 福島圭穣, 岸誠司, 武智研志, 中馬真幸, 座間味義人, 座間味義人, 堀之内裕也 …

臨床薬理, 51(Supplement), 2020
認定薬剤師の科学力を考える基礎研究と医療ビッグデータ解析を融合させたドラッグ・リボジショニングへの試み

堀ノ内裕也, 池田康将, 福島圭穣, 今西正樹, 濱野裕章, 石澤有紀, 座間味義人, 武智研志, 藤野裕道, 石澤啓介 …

臨床薬理, 50(Suppl.) S176-S176, Nov, 2019
大規模医療情報データベースを活用したシスプラチン誘発腎障害に対する新規予防薬の探索とその有効性の検証

合田光寛, 神田将哉, 前川晃子, 新村貴博, 石澤有紀, 座間味義人, 中馬真幸, 武智研志, 濱野裕章, 岡田直人 …

臨床薬理, 50(Suppl.) S246-S246, Nov, 2019
ドラッグリポジショニング手法を用いたバンコマイシン関連腎障害の予防薬探索とその有用性の検討

中馬真幸, 合田光寛, 谷友歩, 座間味義人, 武智研志, 石澤有紀, 濱野裕章, 石田俊介, 新村貴博, 近藤正輝 …

日本腎臓病薬物療法学会誌, 8(特別号) S138-S138, Oct, 2019
大学院生が期待するウェットからドライな薬学研究の未来キサンチンオキシダーゼ阻害剤による新規血管線維化抑制機構の検討

近藤正輝, 今西正樹, 生藤来希, 村井陽一, 福島圭穣, 堀ノ内裕也, 石澤有紀, 合田光寛, 座間味義人, 武智研志 …

日本薬学会年会要旨集, 139年会(1) 328-328, Mar, 2019
慢性腎不全関連サルコペニアにおける鉄代謝異常

堀ノ内裕也, 池田康将, 濱野裕章, 今西正樹, 福島圭穣, 石澤有紀, 合田光寛, 座間味義人, 座間味義人, 武智研志 …

日本サルコペニア・フレイル学会誌, 3(2), 2019
Utilizing Real-World Big Data in the Search for New Renoprotective Drugs

Yuya Horinouchi, Yasumasa Ikeda, Keijo Fukushima, Masaki Imanishi, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami, Hiromichi Fujino, Keisuke Ishizawa, Koichiro Tsuchiya …

HYPERTENSION, 72, Sep, 2018
リアルワールドデータを活用した新規腎保護薬の探索

堀ノ内裕也, 池田康将, 福島圭穣, 石澤有紀, 藤野裕道, 玉置俊晃

日本腎臓学会誌, 60(6) 744-744, Aug, 2018
大規模医療情報を活用した心肺停止患者に対するニコランジルの有効性に関する検討

新村貴博, 座間味義人, 石澤啓介, 今西正樹, 石澤有紀, 堀ノ内裕也, 池田康将, 玉置俊晃, 武智研志, 福島圭穣 …

四国医学雑誌, 74(1-2) 79-80, Apr, 2018
Febuxostatの尿酸合成抑制作用とは独立した血管線維化抑制機構の解明

今西正樹, 近藤正輝, 座間味義人, 石澤啓介, 田中恭平, 生藤来希, 村井陽一, 武智研志, 堀ノ内裕也, 石澤有紀 …

四国医学雑誌, 74(1-2) 80-80, Apr, 2018
大規模医療情報データベース解析と基礎研究の融合による新規腎保護薬の探索

堀ノ内裕也, 池田康将, 石澤有紀, 玉置俊晃, 福島圭穣, 藤野裕道, 濱野裕章, 今西正樹, 座間味義人, 石澤啓介 …

四国医学雑誌, 74(1-2) 82-83, Apr, 2018
大規模医療情報データベースを活用した新規腎保護薬の探索

堀ノ内裕也, 池田康将, 福島圭穣, 今西正樹, 濱野裕章, 石澤有紀, 座間味義人, 座間味義人, 藤野裕道, 石澤啓介 …

医療薬学フォーラム講演要旨集, 26th, 2018
リアルワールドビッグデータを活用した新規腎保護薬の探索

堀ノ内裕也, 池田康将, 福島圭穣, 濱野裕章, 今西正樹, 石澤有紀, 座間味義人, 座間味義人, 武智研志, 藤野裕道 …

日本医療薬学会年会講演要旨集(Web), 28, 2018
新規心肺蘇生薬の開発を目的としたドラッグリポジショニング研究大規模医療情報を活用した検討

新村貴博, 座間味義人, 今西正樹, 石澤啓介, 武智研志, 堀ノ内裕也, 石澤有紀, 池田康将, 玉置俊晃, 藤野裕道 …

四国医学雑誌, 73(5-6) 323-323, Dec, 2017
大規模医療情報を用いて新規心肺蘇生後症候群治療薬の開発を志向したドラッグリポジショニング研究

新村貴博, 座間味義人, 石澤有紀, 今西正樹, 武智研志, 福島圭穣, 堀ノ内裕也, 池田康将, 藤野裕道, 土屋浩一郎 …

臨床薬理, 48(Suppl.) S344-S344, Nov, 2017
ヒトEP4プロスタノイド受容体におけるPGEシリーズのバイアス性

荒木祐美, 藤野裕道, 菅波晃子, 水口博之, Regan John W., 遠藤すず, 田村裕, 村山俊彦

日本薬学会年会要旨集, 137年会(3) 88-88, Mar, 2017
Cyclosporin A has anti-fibrotic effects in human lung fibroblasts and in bleomycin-induced lung fibrosis model mice

Risa Yamazaki, Tetsuo Fujita, Madoka Yanagihara, Hiroyuki Nakamura, Hiromichi Fujino, Yoshitoshi Kasuya, Toshihiko Murayama

FASEB JOURNAL, 30, Apr, 2016
Cyclosporin A has anti-fibrotic effects in human lung fibroblasts and in bleomycin- induced lung fibrosis model mice

Risa Yamazaki, Tetsuo Fujita, Madoka Yanagihara, Hiroyuki Nakamura, Hiromichi Fujino, Yoshitoshi Kasuya, Toshihiko Murayama

FASEB JOURNAL, 30, Apr, 2016
Mapping analysis of mutated cDNA sequences in human DP and EP2 prostanoid receptors

Jun Tanimoto, Hiromichi Fujino, Akihiro Hisaka, Hiroki Takahashi, Toshihiko Murayama

JOURNAL OF PHARMACOLOGICAL SCIENCES, 130(3) S214-S214, Mar, 2016
The effects of immunosuppressants on lung fibrosis

Rica Yamazaki, Yasuo Matsuzawa, Tatsuo Kawashima, Madoka Yanagihara, Hiroyuki Nakamura, Hiromichi Fujino, Toshihiko Murayama

JOURNAL OF PHARMACOLOGICAL SCIENCES, 124 139P-139P, 2014

Research Projects

The expression levels of each EP prostanoid receptor and malignancy of cancer

Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, Apr, 2020 - Mar, 2023

Profile Information

Research Interests

Research Areas

Papers

Misc.

Research Projects

Menu

Coauthors